747 related articles for article (PubMed ID: 26943772)
21. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
[TBL] [Abstract][Full Text] [Related]
22. Physapubescin selectively induces apoptosis in VHL-null renal cell carcinoma cells through down-regulation of HIF-2α and inhibits tumor growth.
Chen L; Xia G; Qiu F; Wu C; Denmon AP; Zi X
Sci Rep; 2016 Sep; 6():32582. PubMed ID: 27581364
[TBL] [Abstract][Full Text] [Related]
23. TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor.
Shang D; Liu Y; Yang P; Chen Y; Tian Y
Urology; 2012 Apr; 79(4):966.e1-7. PubMed ID: 22341602
[TBL] [Abstract][Full Text] [Related]
24. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.
Krishnamachary B; Zagzag D; Nagasawa H; Rainey K; Okuyama H; Baek JH; Semenza GL
Cancer Res; 2006 Mar; 66(5):2725-31. PubMed ID: 16510593
[TBL] [Abstract][Full Text] [Related]
25. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.
Smith K; Gunaratnam L; Morley M; Franovic A; Mekhail K; Lee S
Cancer Res; 2005 Jun; 65(12):5221-30. PubMed ID: 15958567
[TBL] [Abstract][Full Text] [Related]
26. Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
[TBL] [Abstract][Full Text] [Related]
27. Hypoxia-inducible factor (HIF)-prolyl hydroxylase 3 (PHD3) maintains high
Miikkulainen P; Högel H; Seyednasrollah F; Rantanen K; Elo LL; Jaakkola PM
J Biol Chem; 2019 Mar; 294(10):3760-3771. PubMed ID: 30617181
[TBL] [Abstract][Full Text] [Related]
28. von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME.
Tedesco L; Elguero B; Pacin DG; Senin S; Pollak C; Garcia Marchiñena PA; Jurado AM; Isola M; Labanca MJ; Palazzo M; Yankilevich P; Fuertes M; Arzt E
Cell Death Dis; 2019 Mar; 10(4):266. PubMed ID: 30890701
[TBL] [Abstract][Full Text] [Related]
29. Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells.
Sutphin PD; Chan DA; Li JM; Turcotte S; Krieg AJ; Giaccia AJ
Cancer Res; 2007 Jun; 67(12):5896-905. PubMed ID: 17575159
[TBL] [Abstract][Full Text] [Related]
30. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Blancher C; Moore JW; Robertson N; Harris AL
Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
[TBL] [Abstract][Full Text] [Related]
31. miR-122 promotes metastasis of clear-cell renal cell carcinoma by downregulating Dicer.
Fan Y; Ma X; Li H; Gao Y; Huang Q; Zhang Y; Bao X; Du Q; Luo G; Liu K; Meng Q; Zhao C; Zhang X
Int J Cancer; 2018 Feb; 142(3):547-560. PubMed ID: 28921581
[TBL] [Abstract][Full Text] [Related]
32. von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms.
Calzada MJ; Esteban MA; Feijoo-Cuaresma M; Castellanos MC; Naranjo-Suárez S; Temes E; Méndez F; Yánez-Mo M; Ohh M; Landázuri MO
Cancer Res; 2006 Feb; 66(3):1553-60. PubMed ID: 16452212
[TBL] [Abstract][Full Text] [Related]
33. Differential regulation of LncRNA-SARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2α/C-MYC axis under hypoxia.
Zhai W; Sun Y; Jiang M; Wang M; Gasiewicz TA; Zheng J; Chang C
Oncogene; 2016 Sep; 35(37):4866-80. PubMed ID: 26973243
[TBL] [Abstract][Full Text] [Related]
34. TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling.
Zhang X; Li S; He J; Jin Y; Zhang R; Dong W; Lin M; Yang Y; Tian T; Zhou Y; Xu Y; Lei QY; Zhang J; Zhang Q; Xu Y; Lv L
Cancer Res; 2022 Jun; 82(11):2097-2109. PubMed ID: 35176127
[TBL] [Abstract][Full Text] [Related]
35. Functional importance of Dicer protein in the adaptive cellular response to hypoxia.
Ho JJ; Metcalf JL; Yan MS; Turgeon PJ; Wang JJ; Chalsev M; Petruzziello-Pellegrini TN; Tsui AK; He JZ; Dhamko H; Man HS; Robb GB; Teh BT; Ohh M; Marsden PA
J Biol Chem; 2012 Aug; 287(34):29003-20. PubMed ID: 22745131
[TBL] [Abstract][Full Text] [Related]
36. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
Petrella BL; Lohi J; Brinckerhoff CE
Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
[TBL] [Abstract][Full Text] [Related]
37. The uremic toxin p-cresyl sulfate induces proliferation and migration of clear cell renal cell carcinoma via microRNA-21/ HIF-1α axis signals.
Wu TK; Wei CW; Pan YR; Hsu RJ; Wu CY; Yu YL
Sci Rep; 2019 Mar; 9(1):3207. PubMed ID: 30824757
[TBL] [Abstract][Full Text] [Related]
38. VHL and HIF signalling in renal cell carcinogenesis.
Baldewijns MM; van Vlodrop IJ; Vermeulen PB; Soetekouw PM; van Engeland M; de Bruïne AP
J Pathol; 2010 Jun; 221(2):125-38. PubMed ID: 20225241
[TBL] [Abstract][Full Text] [Related]
39. The VHL-dependent regulation of microRNAs in renal cancer.
Neal CS; Michael MZ; Rawlings LH; Van der Hoek MB; Gleadle JM
BMC Med; 2010 Oct; 8():64. PubMed ID: 20964835
[TBL] [Abstract][Full Text] [Related]
40. Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase.
Petrella BL; Brinckerhoff CE
Mol Cancer; 2006 Dec; 5():66. PubMed ID: 17140440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
